Published in PLoS One on April 08, 2013
Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Mol Oncol (2015) 0.87
ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro. Oncotarget (2015) 0.81
Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer. PLoS One (2015) 0.79
CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1α/CXCR4 axis. Mol Cancer (2013) 0.79
Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. Am J Cancer Res (2015) 0.78
Effects of Minocycline on Urine Albumin, Interleukin-6, and Osteoprotegerin in Patients with Diabetic Nephropathy: A Randomized Controlled Pilot Trial. PLoS One (2016) 0.77
Assessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions. Onco Targets Ther (2015) 0.76
Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner. Oncotarget (2016) 0.76
Minocycline promotes the generation of dendritic cells with regulatory properties. Oncotarget (2016) 0.75
Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. Mol Cancer Ther (2016) 0.75
Tetracycline Reduces Kidney Damage Induced by Loxosceles Spider Venom. Toxins (Basel) (2017) 0.75
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem (2003) 4.33
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev (2012) 2.82
Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther (1973) 2.79
The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J (2001) 2.78
Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol (2011) 1.76
Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology (2009) 1.64
Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology (2004) 1.60
The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer (2006) 1.55
Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding. Mol Cell (2011) 1.55
Touched and moved by STAT3. Sci STKE (2006) 1.52
Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett (2010) 1.51
Inflammation and ovarian cancer. Cytokine (2012) 1.49
gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol (2010) 1.48
Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem (2008) 1.41
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 1.37
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res (2010) 1.31
STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.23
CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother Pharmacol (2008) 1.23
Interleukin-6, produced by resident cells of the central nervous system and infiltrating cells, contributes to the development of seizures following viral infection. J Virol (2011) 1.22
STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med (2009) 1.13
Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine (2012) 1.11
Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res (2010) 1.06
STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol Rep (2007) 1.02
Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev (2012) 1.01
Suppression of interleukin-6 by minocycline in a rat model of neuropathic pain. Eur J Pharmacol (2006) 1.00
Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS. PLoS One (2011) 0.99
IL-1beta-stimulated activation of ERK1/2 and p38alpha MAPK mediates the transcriptional up-regulation of IL-6, IL-8 and GRO-alpha in HeLa cells. Cell Signal (2007) 0.99
Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects. Arthritis Res Ther (2011) 0.99
Activation of c-Jun N-terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells. Br J Pharmacol (2010) 0.98
Minocycline reduces astrocytic reactivation and neuroinflammation in the hippocampus of a vascular cognitive impairment rat model. Neurosci Bull (2010) 0.96
Treatment of scleroderma. Arch Dermatol (2002) 0.95
Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des (2012) 0.94
Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol (2012) 0.93
Anti-interleukin-6 receptor antibody inhibits the progression in human colon carcinoma cells. Eur J Clin Invest (2010) 0.92
Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10. Urology (2007) 0.90
Arrest of the proliferation of renal and prostate carcinomas of human origin by inhibition of mitochondrial protein synthesis. Cancer Res (1986) 0.90
4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells. Toxicol Appl Pharmacol (2004) 0.90
Gingival fibroblasts display reduced adhesion and spreading on extracellular matrix: a possible basis for scarless tissue repair? PLoS One (2011) 0.88
Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats. Am J Transl Res (2010) 0.88
Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Gynecol Oncol (2004) 0.88
Modeling resistance to pathway-targeted therapy in ovarian cancer. Cell Cycle (2005) 0.88
Anti-inflammatory properties of doxycycline and minocycline in experimental models: an in vivo and in vitro comparative study. Inflammopharmacology (2011) 0.87
The antitumour effect of doxycycline on a T-cell leukaemia in the rat. Leuk Res (1985) 0.85
Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol (2012) 0.85
Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice. Korean J Physiol Pharmacol (2011) 0.84
Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells. Clin Exp Metastasis (2000) 0.84
Minocycline inhibits alkali burn-induced corneal neovascularization in mice. PLoS One (2012) 0.84
Effect of estrogens on IL-1beta promoter activity. J Steroid Biochem Mol Biol (1998) 0.83
Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways. Gynecol Oncol (2012) 0.82
Estradiol metabolites are potent mitogenic substances for human ovarian cancer cells. Eur J Gynaecol Oncol (2005) 0.82
Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. J Cell Mol Med (2008) 0.81
Minocycline as a therapeutic option in bullous pemphigoid. Clin Exp Dermatol (2001) 0.81
Minocycline in the treatment of acne: latest findings. G Ital Dermatol Venereol (2010) 0.80
Bioactive interleukin-6 levels in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Methods Mol Med (2001) 0.78
Tocilizumab inhibits interleukin-6-mediated matrix metalloproteinase-2 and -9 secretions from human amnion cells in preterm premature rupture of membranes. Gynecol Obstet Invest (2009) 0.78
[Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi (2010) 0.78
[Relationship of IL-6 and IL-8 secretion in epithelial ovarian cancer cell lines with their sensitivity to tamoxifen as well as MAPK, Akt and estrogen receptor phosphorylation]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2010) 0.78
Absorption of minocycline. J Antimicrob Chemother (1984) 0.78
Ovarian epithelial-stromal interactions: role of interleukins 1 and 6. Obstet Gynecol Int (2011) 0.78
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol (2012) 5.06
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol (2009) 3.04
A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol (2007) 2.06
Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg (2010) 1.79
Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol (2008) 1.77
Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer (2008) 1.67
HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol (2010) 1.64
Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol (2009) 1.63
Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet (2011) 1.59
Pulmonary radiofrequency ablation--an international study survey. Anticancer Res (2004) 1.54
Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy. Am J Surg (2010) 1.51
Recurrence after complete cryoablation of colorectal liver metastases: analysis of prognostic features. Am Surg (2006) 1.49
Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival. Ann Surg Oncol (2006) 1.47
Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg (2010) 1.47
Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg (2006) 1.47
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Cancer (2010) 1.46
Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluation of 46 consecutive patients. Ann Surg Oncol (2011) 1.44
Radiofrequency ablation of lung tumors: feasibility and safety. Ann Thorac Surg (2009) 1.42
Hepatectomy and lung radiofrequency ablation for hepatic and subsequent pulmonary metastases from colorectal carcinoma. J Surg Oncol (2007) 1.41
A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol (2009) 1.37
Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol (2009) 1.34
Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol (2009) 1.32
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev (2012) 1.31
Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest (2014) 1.25
Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecol Oncol (2009) 1.23
Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer (2011) 1.21
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg (2008) 1.20
A systematic review of radiofrequency ablation for lung tumors. Ann Surg Oncol (2008) 1.20
Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol (2007) 1.15
Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol (2009) 1.14
Diffuse malignant peritoneal mesothelioma--an update on treatment. Cancer Treat Rev (2011) 1.14
Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol (2009) 1.13
HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor. J Oncol (2012) 1.12
Establishing evidence for change in ovarian cancer surgery--proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecol Oncol (2009) 1.10
Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol (2009) 1.08
Novel protein interactors of urokinase-type plasminogen activator receptor. Biochem Biophys Res Commun (2010) 1.07
Involvement of urokinase-type plasminogen activator system in cancer: an overview. Med Res Rev (2014) 1.06
Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc Hematol Agents Med Chem (2008) 1.06
Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg (2009) 1.06
In-line radiofrequency ablation to minimize blood loss in hepatic parenchymal transection. Am J Surg (2005) 1.05
A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer (2010) 1.05
Percutaneous imaging-guided radiofrequency ablation in patients with colorectal pulmonary metastases: 1-year follow-up. Ann Surg Oncol (2004) 1.05
Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases. Ann Acad Med Singapore (2010) 1.03
Identification of SH2B2beta as an inhibitor for SH2B1- and SH2B2alpha-promoted Janus kinase-2 activation and insulin signaling. Endocrinology (2007) 1.03
Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol (2011) 1.03
Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int (2009) 1.01
Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - a systematic review. Surg Oncol (2012) 1.01
Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev (2012) 1.01
Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol (2011) 1.00
Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: Expert consensus statement. J Surg Oncol (2008) 1.00
Treatment failure after percutaneous radiofrequency ablation for nonsurgical candidates with pulmonary metastases from colorectal carcinoma. Ann Surg Oncol (2007) 1.00
Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2009) 1.00
Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol (2011) 1.00
Percutaneous radiofrequency ablation of lung tumors with expandable needle electrodes: tips from preliminary experience. AJR Am J Roentgenol (2004) 0.99
Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol (2014) 0.98
Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit. J Gastrointest Surg (2010) 0.98
Assessment of complement C4 gene copy number using the paralog ratio test. Hum Mutat (2010) 0.97
Solubilisation and cytotoxicity of albendazole encapsulated in cucurbit[n]uril. Org Biomol Chem (2008) 0.97
Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study. Anticancer Res (2009) 0.97
Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg (2011) 0.96
Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg (2010) 0.96
Learning curve for percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: a prospective study of 70 consecutive cases. Ann Surg Oncol (2006) 0.96
Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol (2012) 0.96
Pseudomyxoma peritonei: a need to establish evidence-based standard of care--is this the right trial? Ann Surg Oncol (2009) 0.95
Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature. J Med Imaging Radiat Oncol (2014) 0.95
Viewing metastatic colorectal cancer as a curable chronic disease. Am J Clin Oncol (2012) 0.94
Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery (2010) 0.94
Critical analysis of 33 patients with peritoneal carcinomatosis secondary to colorectal and appendiceal signet ring cell carcinoma. Ann Surg Oncol (2009) 0.94
Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. Int J Clin Oncol (2012) 0.93
Neuropeptide Y is produced by adipose tissue macrophages and regulates obesity-induced inflammation. PLoS One (2013) 0.93
A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol (2013) 0.93
Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine (Baltimore) (2015) 0.93
Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy. Ann Surg (2012) 0.93
Pelvic exenteration for rectal cancer: a systematic review. Dis Colon Rectum (2013) 0.93
Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. Cancer Chemother Pharmacol (2010) 0.92
Large volume hepatic freezing: association with significant release of the cytokines interleukin-6 and tumor necrosis factor a in a rat model. World J Surg (2002) 0.92
Outcomes of elderly patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal cancer peritoneal carcinomatosis. J Surg Oncol (2011) 0.92
Optimizing radioimmunoconjugate delivery in the treatment of solid tumor. Cancer Treat Rev (2012) 0.91
Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases--a systematic review. Eur J Cancer (2011) 0.91
Divergent compensatory responses to high-fat diet between C57BL6/J and C57BLKS/J inbred mouse strains. Am J Physiol Endocrinol Metab (2013) 0.91
Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol (2010) 0.91
Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol (2004) 0.91
Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Anticancer Res (2009) 0.90
Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Lett (2010) 0.90
Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients. Ann Surg Oncol (2013) 0.90
Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J Surg Oncol (2011) 0.90
Hepatic cryotherapy and regional chemotherapy with or without resection for liver metastases from colorectal carcinoma: how many are too many? Cancer (2003) 0.89